181. Protitumorska učinkovitost genskega elektroprenosa plazmidne dna z zapisom za rekombinatno protitelo proti CTLA-4 v kombinaciji z obsevanjemBoštjan Markelc, Simona Kranjc Brezar, Tanja Jesenko, Tim Božič, Maja Čemažar, Liesl Jacobs, Kevin Hollevoet, Gregor Serša, 2022, objavljeni povzetek znanstvenega prispevka na konferenci Ključne besede: obsevanje, genski elektroprenos, eksperimentalna onkologija Objavljeno v DiRROS: 17.06.2022; Ogledov: 636; Prenosov: 207 Celotno besedilo (80,83 KB) |
182. Aktivacija cGAS-STING signalne poti po obsevanju humanih tumorskih modelov karcinomov žrelaKristina Levpušček, Simona Kranjc Brezar, Tanja Jesenko, Gregor Serša, Maja Čemažar, Primož Strojan, 2022, objavljeni povzetek znanstvenega prispevka na konferenci Ključne besede: rak žrela, tumorski modeli, eksperimentalna onkologija Objavljeno v DiRROS: 17.06.2022; Ogledov: 617; Prenosov: 191 Celotno besedilo (80,79 KB) |
183. Izločanje dejavnika imunogene celične smrti HMGB1 iz celičnih linij se povečuje z dozo obsevanjaUrša Kešar, Tanja Jesenko, Boštjan Markelc, Katja Uršič Valentinuzzi, Maja Čemažar, Primož Strojan, Gregor Serša, 2022, objavljeni povzetek znanstvenega prispevka na konferenci Ključne besede: ionizirajoče sevanje, geni, eksperimentalna onkologija Objavljeno v DiRROS: 17.06.2022; Ogledov: 662; Prenosov: 176 Celotno besedilo (80,66 KB) |
184. Učinki obsevanja dela tumorja na imunske populacije na tumorskem modelu mišjega karcinoma dojke 4T1Tanja Jesenko, Živa Modic, Tim Božič, Simona Kranjc Brezar, Ilija Vojvodić, Božidar Casar, Ignasi Méndez Carot, Maja Čemažar, Gregor Serša, Boštjan Markelc, 2022, objavljeni povzetek znanstvenega prispevka na konferenci Ključne besede: radioterapija, tumorski modeli, eksperimentalna onkologija Objavljeno v DiRROS: 17.06.2022; Ogledov: 642; Prenosov: 184 Celotno besedilo (80,61 KB) |
185. |
186. |
187. |
188. Insight into the interdependence of Ni and Al in bifunctional Ni/ZSM-5 catalysts at the nanoscaleHue-Tong Vu, Iztok Arčon, Danilo Oliveira de Souza, Simone Pollastri, Goran Dražić, Janez Volavšek, Gregor Mali, Nataša Zabukovec Logar, Nataša Novak Tušar, 2022, izvirni znanstveni članek Ključne besede: Ni/ZSM-5 catalysts, zeolite, Ni XANES, EXAFS Objavljeno v DiRROS: 13.06.2022; Ogledov: 789; Prenosov: 405 Celotno besedilo (1,25 MB) Gradivo ima več datotek! Več... |
189. P14/ARF-positive malignant pleural mesothelioma : ǂa ǂphenotype with distinct immune microenvironmentFederica Pezzuto, Francesca Lunardi, Luca Vedovelli, Francesco Fortarezza, Loredana Urso, Federica Grosso, Giovanni Luca Ceresoli, Izidor Kern, Gregor Vlačić, Fiorella Calabrese, 2022, izvirni znanstveni članek Povzetek: Introduction: The CDKN2A gene plays a central role in the pathogenesis of malignant pleural mesothelioma (MPM). The gene encodes for two tumor suppressor proteins, p16/INK4A and p14/ARF, frequently lost in MPM tumors. The exact role of p14/ARF in MPM and overall its correlation with the immune microenvironment is unknown. We aimed to determine whether there is a relationship between p14/ARF expression, tumor morphological features, and the inflammatory tumor microenvironment. Methods: Diagnostic biopsies from 76 chemo-naive MPMs were evaluated. Pathological assessments of histotype, necrosis, inflammation, grading, and mitosis were performed. We evaluated p14/ARF, PD-L1 (tumor proportion score, TPS), and Ki-67 (percentage) by immunohistochemistry. Inflammatory cell components (CD3+, CD4+, CD8+ T lymphocytes; CD20+ B-lymphocytes; CD68+ and CD163+ macrophages) were quantified as percentages of positive cells, distinguishing between intratumoral and peritumoral areas. The expression of p14/ARF was associated with several clinical and pathological characteristics. A random forest-based machine-learning algorithm (Boruta) was implemented to identify which variables were associated with p14/ARF expression. Results: p14/ARF was evaluated in 68 patients who had a sufficient number of tumor cells. Strong positivity was detected in 14 patients (21%) (11 epithelioid and 3 biphasic MPMs). At univariate analysis, p14/ARF-positive epithelioid mesotheliomas showed higher nuclear grade (G3) (p = 0.023) and higher PD-L1 expression (≥50%) (p = 0.042). The percentages of CD4 and CD163 in peritumoral areas were respectively higher and lower in p14/ARF positive tumors but did not reach statistical significance with our sample size (both p = 0.066). The Boruta algorithm confirmed the predictive value of PD-L1 percentage for p14/ARF expression in all histotypes. Conclusions: p14/ARF-positive epithelioid mesotheliomas may mark a more aggressive pathological phenotype (higher nuclear grade and PD-L1 expression). Considering the results regarding the tumor immune microenvironment, p14/ARF-negative tumors seem to have an immune microenvironment less sensitive to immune checkpoint inhibitors, being associated with low PD-L1 and CD4 expression, and high CD163 percentage. The association between p14/ARF-positive MPMs and PD-L1 expression suggests a possible interaction of the two pathways. Confirmation of our preliminary results could be important for patient selection and recruitment in future clinical trials with anticancer immunotherapy. Ključne besede: lung -- cytology -- pathology, neoplasms, malignant mesothelioma, malignant pleural mesothelioma, tumor microenvironment Objavljeno v DiRROS: 30.05.2022; Ogledov: 783; Prenosov: 507 Celotno besedilo (13,14 MB) Gradivo ima več datotek! Več... |
190. |